Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Eupraxia Pharmaceuticals Inc: Eupraxia closes $44.52-million private placement | 1 | Stockwatch | ||
Fr | Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million | 2 | CNW | ||
Mo | Stocks in Play: Eupraxia Pharmaceuticals Inc. | - | Baystreet.ca | ||
Mo | Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 | 3 | CNW | ||
Mo | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.10. | Eupraxia Pharmaceuticals Inc: Eupraxia's EP-104IAR trial data published in Lancet | 3 | Stockwatch | ||
15.10. | Eupraxia reports Phase 2b trial success for osteoarthritis treatment | 1 | Investing.com | ||
15.10. | Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis | 1 | CNW | ||
10.10. | Eupraxia Pharmaceuticals reports to SEC on latest developments | 1 | Investing.com | ||
10.10. | Eupraxia Pharmaceuticals reicht Bericht bei der SEC ein | 1 | Investing.com Deutsch | ||
10.10. | Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 | 1 | CNW | ||
10.10. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
08.10. | EPRX-Aktie erreicht 52-Wochen-Tief bei 2,34 US-Dollar | - | Investing.com Deutsch | ||
08.10. | EPRX stock touches 52-week low at $2.34 amid market challenges | 1 | Investing.com | ||
03.10. | Eupraxia Pharmaceuticals files report with SEC | 1 | Investing.com | ||
02.10. | Eupraxia Pharmaceuticals Inc: Eupraxia appoints scientific officer, executive VP | 2 | Stockwatch | ||
02.10. | Eupraxia Pharmaceuticals expands leadership team | 1 | Investing.com | ||
02.10. | Eupraxia Pharmaceuticals Strengthens Senior Management Team | 1 | CNW | ||
02.10. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
20.09. | Eupraxia Pharmaceuticals files report with SEC | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,730 | +1,74 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
ADMA BIOLOGICS | 19,245 | +18,00 % | ADMA Biologics jumps as KPMG becomes new auditor | ||
EVOTEC | 7,145 | +0,78 % | Evotec Aktie: Ein Mosaik des Wachstums! | Die Evotec-Aktie erlebt derzeit einen bemerkenswerten Aufschwung. Nach einem drastischen Kursverfall von 70% seit Jahresbeginn hat das Hamburger Biotechnologieunternehmen durch eine erweiterte Kooperation... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,120 | +3,08 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,68 | -0,08 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
BIONTECH | 102,40 | -0,87 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 9,160 | +22,30 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
NUVALENT | 88,46 | -0,03 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results | Company plans to host a conference call in conjunction with oral presentations at ESMO on September 14, 2024, at 8:30 a.m. ET / 2:30 p.m. CEST
$658.0 million in cash, cash equivalents and marketable... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,435 | +1,82 % | Recursion Pharmaceuticals-Direktor Blake Borgeson verkauft Aktien im Wert von 76.926 US-Dollar | ||
SUMMIT THERAPEUTICS | 18,860 | +1,45 % | Summit Therapeutics Aktie: Bleiben Sie wachsam! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnete am 26. Oktober 2024 einen bemerkenswerten Kursanstieg von 9,25% auf 21,26 USD. Dieser Aufschwung erfolgt trotz einer herausfordernden... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 42,100 | -0,38 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
VERA THERAPEUTICS | 43,500 | +7,73 % | Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 | Long-term improvements observed in the quartet of findings defining disease modification supports atacicept's potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 47,100 | +5,87 % | Tarsus Pharmaceuticals stock hits 52-week high at $42.63 | ||
TANGO THERAPEUTICS | 5,130 | -5,61 % | TNGX-Aktie erreicht 52-Wochen-Tief bei 5,6 US-Dollar | ||
ATHIRA PHARMA | 0,625 | +45,99 % | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen |